Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid MalignanciesDavid Olmos, Sarah P. Blagden, André T. Brunetto et al.|Clinical Cancer Research|2011Cited by 168
Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumorsDavid Olmos, Sarah P. Blagden, Alicia J. Allred et al.|Journal of Clinical Oncology|2009Cited by 22